TScan Therapeutics, Inc.
TCRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $340,451 | $382,447 | $37,275 | $107,584 |
| - Cash | $178,689 | $133,359 | $120,027 | $161,405 |
| + Debt | $97,381 | $92,433 | $85,984 | $6,043 |
| Enterprise Value | $259,143 | $341,521 | $3,232 | -$47,778 |
| Revenue | $2,816 | $21,049 | $13,535 | $10,141 |
| % Growth | -86.6% | 55.5% | 33.5% | – |
| Gross Profit | $2,816 | $21,049 | $13,535 | $10,141 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$119,738 | -$80,098 | -$59,908 | -$45,297 |
| % Margin | -4,252.1% | -380.5% | -442.6% | -446.7% |
| Net Income | -$127,499 | -$89,218 | -$66,221 | -$48,625 |
| % Margin | -4,527.7% | -423.9% | -489.3% | -479.5% |
| EPS Diluted | -1.14 | -1.36 | -2.74 | -2.03 |
| % Growth | 16.2% | 50.4% | -35% | – |
| Operating Cash Flow | -$110,822 | -$61,358 | -$66,503 | -$48,677 |
| Capital Expenditures | -$3,825 | -$3,146 | -$4,225 | -$9,941 |
| Free Cash Flow | -$114,647 | -$64,504 | -$70,728 | -$58,618 |